EMA adopts positive opinion for Keytruda in melanoma following complete resection
Source: The Cancer Letter, May 2022
A committee of the European Medicines Agency recommended the approval for expanded use of Keytruda (pembrolizumab) as a standalone therapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma who have undergone complete resection.
